- Home
- PTA vs COLL Comparison
PTA vs COLL Comparison
Compare PTA & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTA
- COLL
- Stock Information
- Founded
- PTA 2020
- COLL 2002
- Country
- PTA United States
- COLL United States
- Employees
- PTA N/A
- COLL N/A
- Industry
- PTA Trusts Except Educational Religious and Charitable
- COLL Biotechnology: Pharmaceutical Preparations
- Sector
- PTA Finance
- COLL Health Care
- Exchange
- PTA Nasdaq
- COLL Nasdaq
- Market Cap
- PTA 1.1B
- COLL 1.0B
- IPO Year
- PTA N/A
- COLL 2015
- Fundamental
- Price
- PTA $19.97
- COLL $30.77
- Analyst Decision
- PTA
- COLL Strong Buy
- Analyst Count
- PTA 0
- COLL 5
- Target Price
- PTA N/A
- COLL $43.60
- AVG Volume (30 Days)
- PTA 159.2K
- COLL 441.9K
- Earning Date
- PTA 01-01-0001
- COLL 02-20-2025
- Dividend Yield
- PTA 8.31%
- COLL N/A
- EPS Growth
- PTA N/A
- COLL 757.11
- EPS
- PTA N/A
- COLL 2.16
- Revenue
- PTA N/A
- COLL $599,245,000.00
- Revenue This Year
- PTA N/A
- COLL $13.25
- Revenue Next Year
- PTA N/A
- COLL $18.14
- P/E Ratio
- PTA N/A
- COLL $14.24
- Revenue Growth
- PTA N/A
- COLL 9.62
- 52 Week Low
- PTA $15.84
- COLL $28.39
- 52 Week High
- PTA $19.67
- COLL $42.29
- Technical
- Relative Strength Index (RSI)
- PTA 61.24
- COLL 45.90
- Support Level
- PTA $19.80
- COLL $32.28
- Resistance Level
- PTA $20.03
- COLL $33.45
- Average True Range (ATR)
- PTA 0.16
- COLL 1.07
- MACD
- PTA 0.05
- COLL -0.16
- Stochastic Oscillator
- PTA 81.95
- COLL 2.05
About PTA Cohen & Steers Tax-Advantaged Preferred Securities and Income Fund of Beneficial Interest
COHEN & STEERS TAX-ADV PRD SEC AND INC is a non-diversified, closed-end management statutory trust. Its primary investment objective is high current income, and the Fund's secondary investment objective is capital appreciation.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.